Virtus Biotech Clinical Trials ETF
BBC
20 hedge funds and large institutions have $19.9M invested in Virtus Biotech Clinical Trials ETF in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
61% more capital invested
Capital invested by funds: $12.3M → $19.9M (+$7.56M)
4.87% more ownership
Funds ownership: 34.82% → 39.69% (+4.9%)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$3.06M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$653K |
| 3 |
KCP
Kera Capital Partners
San Jose,
California
|
+$519K |
| 4 |
Goldman Sachs
New York
|
+$387K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$584K |
| 2 |
APW
Aurora Private Wealth
Rockaway,
New Jersey
|
-$474K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
-$432K |
| 4 |
Jane Street
New York
|
-$315K |
| 5 |
GAA
Global Assets Advisory
Orlando,
Florida
|
-$104K |
BBC Hedge Fund Activity: Q2 2026 in Review
20 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2026, worth a combined $19.9M — up 61% from $12.3M a quarter earlier.
Fund positioning in BBC was balanced in Q2 2026: 7 funds opened new positions, 7 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Wealth Enhancement Advisory Services, opening a new position worth an estimated $3.06M. The largest seller was Susquehanna International Group, cutting an estimated $584K.
- 20 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $19.9M of Virtus Biotech Clinical Trials ETF stock for Q2 2026, up 61% quarter-over-quarter.
- 7 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2026 and 7 closed out, a net change of 0 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2026 was Wealth Enhancement Advisory Services, an estimated $3.06M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q2 2026 was Susquehanna International Group, an estimated $584K sold.
Based on aggregated 13F filings for Q2 2026.